Unless you’re living under a rock, you’re well aware of the gains in technology (and own a lot of it). Since ChatGPT’s launch ...

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.

Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the ...

One reported that The Economist – not exactly Israel’s biggest cheerleader – ranked the Jewish state third in its annual survey of the world’s strongest economies in 2025. The stock market was named ...

Located in Rockville, Maryland, GSK's Human Genome Sciences will be Samsung Biologics' first U.S.-based manufacturing site. | ...

Samsung Biologics America, a subsidiary of Samsing Biologics, a CDMO, has entered into a definitive agreement to acquire 100% ...

Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making ...

Samsung Biologics has agreed to buy GSK's Human Genome Sciences for $280 million, expanding the company's footprint into the U.S. market.

SEOUL, Dec 22 (Reuters) - South Korea's Samsung Biologics (207940.KS) said on Monday it is acquiring its first U.S. drug ...

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply networkAdditional investments planned to expand the site's capacity (currently at 60,000 ...

Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront and ...

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a 2020 licensing agreement. The breakup was initiated by GSK on Dec. 4, Ideaya ...